Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 164 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antiemetics Clear all
Terminated Phase 4 Interventional Results available

Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery

NCT02724033
View directory record Official record
Conditions
Anesthesia, Pediatrics, Surgery
Interventions
regional nerve block, Antiemetic
Procedure · Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

NCT00326248
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
GW679769 (casopitant)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
26
States / cities
Montgomery, Alabama • Sheffield, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

NCT00600990
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW597599
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

NCT00598507
View directory record Official record
Conditions
Melanoma
Interventions
ZK-EPO
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00895245
View directory record Official record
Conditions
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy
Drug · Other · Behavioral + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions
Imexon
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery

NCT01449708
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
TIVA NoNarc
Drug
Lead sponsor
Coastal Anesthesiology Consultants
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Saint Augustine, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Low Dose Aprepitant for Patients Receiving Carboplatin

NCT03237611
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Aprepitant 125 mg, Fosaprepitant 115 MG, Dexamethasone, Ondansetron 16 MG
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 3, 2026, 9:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

NCT00738621
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Dexamethasone, Ondansetron, Aprepitant, Dexamethasone, Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 3, 2026, 9:50 AM EDT
Recruiting Phase 4 Interventional

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

NCT04150614
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 3, 2026, 9:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Interventions
Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acupuncture ACL (Anterior Cruciate Ligament)

NCT03711734
View directory record Official record
Conditions
ACL, ACL Injury, Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture, Anesthesia
Interventions
Acupuncture + Standard of Care
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
12 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 3, 2026, 9:50 AM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy

NCT00734929
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant + Dexamethasone, Ondansetron + Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 3, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

NCT00216138
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Capecitabine, Premedication
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Newark, Delaware • Chicago, Illinois • Elkhart, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755
View directory record Official record
Conditions
Lymphoma
Interventions
Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Efficacy of Aprepitant (Emend®) in Children

NCT01661335
View directory record Official record
Conditions
Nausea, Vomiting, Childhood Cancer
Interventions
Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 20 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

NCT02337062
View directory record Official record
Conditions
PONV
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
14
States / cities
Sheffield, Alabama • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia

NCT03197064
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Fosaprepitant 150 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984
View directory record Official record
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 3, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
aprepitant, ondansetron, dexamethasone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 3, 2026, 9:50 AM EDT